We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 29

Sidley Austin LLP global pricing newsletter - volume three 2014

  • Sidley Austin LLP
  • -
  • Brazil, Canada, China, European Union, France, Germany, India, United Kingdom, USA
  • -
  • April 15 2014

On October 21, 2013, Brazil’s National Agency of Supplemental Health enacted Normative Resolution 388, which mandated that all private healthcare

French Competition Authority fines pharmaceutical Laboratory EUR 15.3 million for hindering the launch of generic equivalent

  • Bryan Cave LLP
  • -
  • France
  • -
  • March 14 2014

In an important decision of December 18, 2013, the French Competition Authority ("FCA") fined Schering-Plough and its parent companies a total of EUR

Johnson & JohnsonNovartis another challenge to pay for delay: is this ever permissible?

  • Bryan Cave LLP
  • -
  • European Union, France, Germany, Italy, United Kingdom
  • -
  • January 14 2014

In the latest challenge to so-called “pay for delay” or “reverse payment” agreements, on 10 December 2013, the European Commission fined the

France - Public consultation into the pharmaceutical sector

  • Hogan Lovells
  • -
  • France
  • -
  • September 1 2013

The French Competition Authority has launched on 10 July 2013 a public Consultation entitled "How to revitalize competition in the distribution of

The Autorité de la concurrence French Competition Authority is launching a public consultation on the distribution of medicinal products in private practices.

  • Baker & McKenzie
  • -
  • France
  • -
  • July 24 2013

The Autorité de la concurrence ("Autorité") has submitted its preliminary assessment to a public consultation on 10 July 2013 on the

Life sciences: 2013 legal developments you need to know about

  • Mayer Brown LLP
  • -
  • China, European Union, France, USA
  • -
  • July 16 2013

This is a short guide outlining some of the key legal developments in the life sciences sector in 2013. The developments include the Supreme Court

A 40.6 million fine imposed on Sanofi-Aventis for its disparagement of competitors’ generic drugs

  • Dentons
  • -
  • France
  • -
  • June 25 2013

Recent events show that competition authorities actively pursue and heavily punish anti-competitive practices that aim to delay the marketing of

French Competition Authority fines Sanofi-Aventis EUR 40.6 million for disparaging competing generic products

  • Baker Botts LLP
  • -
  • France
  • -
  • May 31 2013

On 14 May 2013, the French Autorité de la concurrence ("Autorité") fined Sanofi-Aventis ("Sanofi") EUR 40.6 million (approximately USD

France - notice of the French Competition Authority on the online sale of drugs

  • Hogan Lovells
  • -
  • France
  • -
  • May 31 2013

Opinion n13-A-12 of 10 April 2013 of the French Competition Authority on a draft decree relating to good practices in the dispensing of

Kartellrechtliche fallstricke im life science-bereich

  • Baker & McKenzie
  • -
  • European Union, France, USA
  • -
  • May 24 2013

Im Wettbewerb gegen Generika ist Vorsicht geboten: Verschiedene Maßnahmen gegen den Markteintritt kostengünstigerer Generika werden